Mikhail Martchenko, PhDAssistant Professor
Areas of Expertise
Host - Pathogen Interactions, Infectious Diseases, Human Genetics, Drug Discovery and Development
Dr. Martchenko received his BS in biochemistry in 2002 from Concordia University (Montreal, Canada), and his PhD in biology in 2007 from McGill University. After completing his postdoctoral studies at Stanford University School of Medicine, he joined KGI as an Assistant Professor.
Dr. Martchenko is interested in studying infectious diseases and host - pathogen interactions. His current research searches for ways to treat and prevent anthrax and Candida infections.
ALS 330: Pharmaceutical Discovery
This course is designed to provide you with an understanding of how pharmaceutical and biotechnology companies discover new drugs. This course will focus on the discovery of small molecule drugs.ALS 430: Advanced Pharmaceutical Discovery
This course should provide the student with a deeper understanding of how pharmaceutical and biotechnology companies discover new drugs, and how larger companies manage their drug discovery portfolios
- Selected Publications
Jeong SY, Martchenko M, Cohen SN. Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis.
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4007-15
Martchenko M, Candille SI, Tang H, Cohen SN. Human genetic variation altering anthrax toxin sensitivity.
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2972-7
Martchenko M, Jeong SY, Cohen SN. Heterodimeric integrin complexes containing beta1 integrin promote internalization and lethality of anthrax toxin.
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15583-8
Martchenko M, Levitin A, Hogues H, Nantel A, and Whiteway M. Transcriptional rewiring of fungal galactose-metabolism circuitry.
Current Biology (Cell Press). 2007 Jun 19;(17):1-7
van Het Hoog M*, Rast TJ*, Martchenko M, Grindle S, Dignard D, Hogues H, Berriman M, Scherer S, Magee BB, Whiteway M, Chibana H, Nantel A, Magee PT. Assembly of the Candida albicans genome into sixteen supercontigs aligned on the eight chromosomes.
Genome Biol. 2007 Apr 9;8(4):R52
Martchenko M, Levitin A, Whiteway M. Transcriptional activation domains of the Candida albicans Gcn4p and Gal4p homologs.
Eukaryot Cell. 2007 Feb;6(2):291-301
Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A, Inglis DO, Uhl MA, Hogues H, Berriman M, Lorenz M, Levitin A, Oberholzer U, Bachewich C, Harcus D, Marcil A, Dignard D, Iouk T, Zito R, Frangeul L, Tekaia F, Rutherford K, Wang E, Munro CA, Bates S, Gow NA, Hoyer LL, Köhler G, Morschhäuser J, Newport G, Znaidi S, Raymond M, Turcotte B, Sherlock G, Costanzo M, Ihmels J, Berman J, Sanglard D, Agabian N, Mitchell AP, Johnson AD, Whiteway M, Nantel A. A human-curated annotation of the Candida albicans genome.
PLoS Genet. 2005 Jul;1(1):36-57
Martchenko M, Alarco AM, Harcus D, and Whiteway M. Superoxide dismutases in Candida albicans: transcriptional regulation and functional characterization of the hyphal-induced SOD5 gene.
Mol Biol Cell. 2004 Feb;15(2):456-67
Dr. Martchenko's prior work in the host-pathogen field has focused on the discoveries of virulence strategies of human pathogens Candida albicans and Bacillus anthracis (anthrax), understanding of how they exploit human hosts, and evaluation of therapeutic intervention points. He found that human genetic variation within genes exploited by pathogens alters the sensitivity of hosts to the adverse effects of infectious microbes.
By combining advanced genetic, biochemical, evolutionary, and bioinformatics approaches, Dr. Martchenko's ongoing research investigates pathogenic strategies of medically important fungal pathogen Candida albicans, and toxins of bacterial pathogen Bacillus anthracis, with the ultimate aim of discovering and evaluating approaches that will allow effective therapeutic interventions. His research specializes in advancing our understanding of bacterial and fungal pathogens, which is important from medical, veterinary, academic, and bio-defense points of view.
CURRENT RESEARCH PROJECTS:
Project 1: Small molecule drug discovery and development against anthrax.
Project 2: The development of next-generation anthrax vaccine.
Project 3: Identification of human genetic variation affecting host sensitivity to anthrax.
Project 4: Drug discovery against human fungal pathogen, Candida albicans.
"Methods and Compositions for Preventing and Treating an Anthrax Toxin Mediated Condition in a Subject", Mikhail Martchenko, Sun-Young Jeong, and Stanley N. Cohen. U.S. Provisional Application Serial No. 61/523,693. Filing date August 15, 2011.
|Mikhail Martchenko, PhD|
|Location:||Building 535, Room 140|